Neurocrine Biosciences FY Conference Summary Company Overview - **Company**: Neurocrine Biosciences (NasdaqGS:NBIX) - **Key Products**: INGREZZA and CRENESSITY - **Market Position**: Operating from a position of strength with two commercial value drivers and a strong R&D engine [4][8] Core Strengths - **Commercial Value Drivers**: - **INGREZZA**: Experienced double-digit volume growth in 2025, with expectations for continued growth in 2026. It is the lowest-priced VMAT2 inhibitor with the best clinical performance [5][6] - **CRENESSITY**: Achieved over $300 million in sales in its first year post-approval for congenital adrenal hyperplasia, indicating a strong trajectory towards blockbuster status [6][12] - **R&D Engine**: A fully operational and sustainable R&D engine capable of producing multiple high-quality programs, particularly in neurology and psychiatry [7][8] - **Financial Strength**: High-margin, cash-generative business model providing resiliency and optionality for capital allocation [8][9] - **Proven Team**: Experienced in launching medicines and executing clinical studies [9][10] Challenges and Risks - **IRA Impact**: The Inflation Reduction Act (IRA) poses a headwind for the industry and specifically for INGREZZA, with preparations in place for its implementation in 2029 [10][11] - **CRENESSITY Launch Dynamics**: Initial patient start fluctuations are common in orphan drug launches, but underlying demand remains strong [11][12] - **Investment Strategy**: Focus on long-term growth rather than maximizing short-term profits, with investments in SG&A and R&D aligned with peer benchmarks [12][13] Key Priorities for 2026 - Achieve double-digit volume growth for INGREZZA [14] - Successfully scale the CRENESSITY launch and expand the patient population [14] - Execute on the mid to late-stage pipeline to deliver data in the coming years [14] Market Dynamics - **INGREZZA Growth Drivers**: Continued growth in the VMAT2 category, increasing prevalence of tardive dyskinesia (TD), and expanding prescriber base [18][19] - **CRENESSITY Market Penetration**: Currently treating about 10% of the total prevalent patient pool, with expectations for continued growth [25][26] R&D Strategy - **Therapeutic Areas**: Diversification into neurology, endocrinology, and neuroimmunology while maintaining a strong focus on neuropsychiatry [40][41] - **Modalities**: Transitioning from a small molecule focus to include peptides, proteins, antibodies, and gene therapy [42] - **Innovation Philosophy**: Emphasis on pragmatic innovation targeting proven biology, with a balanced portfolio of high-confidence targets [43] Obesity Market Strategy - **Emerging Focus**: Neurocrine is positioning itself in the obesity market, emphasizing quality weight loss and addressing comorbidities [45][46] - **Pipeline Development**: Plans to advance multiple molecules targeting obesity, leveraging existing expertise in CNS [49][50] Financial Projections - **Revenue Estimates**: Projected revenue of $301 million for CRENESSITY in 2026, with potential for significant growth by 2030 [29][32] Conclusion - Neurocrine Biosciences is well-positioned for growth with a strong product portfolio, robust R&D capabilities, and a clear strategy for navigating market challenges and opportunities in the coming years [14][44]